Immunotherapy

 

The immune system is a system of cells and organs whose function is to defend an organism from foreign pathogens. With the ability to mount a response against virtually any foreign material and return to a quiescent state following neutralization of the threat, this fascinating organ system displays remarkable specificity and plasticity. To achieve this, there is a multifaceted balancing act between the many activators and suppressors that maintains homeostasis of perhaps the body’s most complex organ system.

Activation of the immune system involves a number of checkpoints in order to ensure proper activation. For instance, T cell activation requires binding of the T cell receptor to the MHC antigen, yet this interaction alone is not sufficient for producing a T cell response. Full T cell activation and inactivation requires the coordination of a multitude of co-stimulatory and inhibitory signals. For example, T cell activation can result from the combination of MHC:TCR and B7-1:CD28 interaction. In contrast, B7-1 binding to CTLA4 results in an inhibitory signal that prevents activation.

Given its diverse function and the fact that the immune system plays a role in virtually all human diseases, immunotherapy has become an important approach for the treatment of numerous diseases. Immunotherapy is defined as the treatment of disease by inducing, enhancing, or suppressing an immune response. This often involves targeting immunoreceptors, such as those discussed above, with small molecule inhibitors/activators or immune system components, including antibodies or antibody fragments (Fab). Immunotherapies have shown efficacy in the treatment of cancer, autoimmune diseases, inflammatory diseases, and more.

BPS Bioscience offers many purified, soluble immunoreceptors involved in key immunosignaling pathways. Additionally, we offer a number of assay kits that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies to serve as positive controls for inhibition.

References:

1.  Pardoll, D.M., Nat. Rev. Cancer. 2012; 12: 252-264.
2.  Lesterhuis, W.J., et al., Nat. Rev. Drug. Disc. 2011; 10: 591-600.

Immunotherapy Subcategories

Items 76 to 100 of 480 total

per page
Page:
  1. 2
  2. 3
  3. 4
  4. 5
  5. 6

Catalog#SizeProduct NamePrice
79385 100 ml BPS Medium 8
$100
79476 2 Vials BTLA / NFAT - Luciferase Reporter - Jurkat Recombinant Cell Line
$8,000
71141 100 µg BTLA(CD272), Fc fusion (Human)
$310
100033 100 µg BTLA, Fc Fusion, Avi-Tag HiP™
$310
100047 50 µg BTLA, Fc Fusion, Avi-Tag, Biotin-Labeled HiP™
$420
72008 96 reactions BTLA:HVEM[Biotinylated] Inhibitor Screening Assay Kit
$1,040
40254 10 µg c-Mer, GST-tag (Human)
$375
80413 50 µg CBL-B (Y363F), His-tag, Biotin-labeled (Human)
$370
80412 50 µg CBL-B, His-tag, Biotin-labeled (Human)
$370
77001 100 μg CD111, Fc-Fusion, Avi-Tag
$310
77002 50 μg CD111, Fc-Fusion, Avi-Tag, Biotin-Labeled HiP™
$420
72231 50 μg CD112, Fc-Fusion, Avi-Tag, Biotin-labeled (Human)
$420
71197 100 μg CD112, His-tag (Human) HiP™
$310
79116 100 μg CD112R, Fc-Fusion, Avi-Tag (Human) HiP™
$310
79270 50 μg CD112R, Fc-Fusion, Avi-Tag, Biotin-Labeled (Human) HiP™
$420
72510 100 μg CD113, Fc-Fusion (IgG1), Avi-Tag
$310
100068 50 µg CD123, Fc-Fusion (IgG1) Avi-Tag, Biotin-Labeled
$420
60691 2 vials CD137 (4-1BB) HEK293 Recombinant Cell Line
$3,650
71170 100 µg CD137 (4-1BB), Fc fusion (Human) HiP™
$300
71171 50 µg CD137 (4-1BB), Fc Fusion, Biotin-labeled (Human) HiP™
$405
71250 100 μg CD137, Fc fusion (hIgG1) (Mouse)
$310
71254 100 µg CD137, Fc fusion (mIgG2a), Avi-tag (Mouse) HiP™
$310
71255 50 µg CD137, Fc fusion (mIgG2a), Biotin-labeled (Mouse) HiP™
$420
79289 2 vials CD137/NF-κB Reporter - HEK293 Recombinant Cell Line
$8,000
71189 100 µg CD137L (4-1BB ligand), His-tag
$310

Items 76 to 100 of 480 total

per page
Page:
  1. 2
  2. 3
  3. 4
  4. 5
  5. 6